• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

SEC meets to discuss EUA applications from Pfizer, SII and Bharat Biotech

expresspharmaDecember 31, 2020

Tag: SEC , SII , Bharat Biotech

The Subject Expert Committee (SEC) in the Central Drugs Standard Control Organisation (CDSCO) met on December 30, 2020, in the afternoon to consider the Emergency Use Authorisation (EUA) requests of Pfizer, Serum Institute of India (SII) and Bharat Biotech.

Further time was requested on behalf of Pfizer. The additional data and information presented by SII and Bharat Biotech were perused and analysed by the SEC.

The analysis of the additional data and information is going on. SEC will convene again on January 1, 2021.

Previous:Recipharm, Moderna sign deal for manufacturing, fill-finish of COVID-19 vaccines

Next:Awaiting India’s approval for COVISHIELD: SII

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

SEC meets to discuss EUA applications from Pfizer, SII and Bharat Biotech | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

The secondary fermentation tank

The secondary fermentation tank
di-sec-butyldisulfide（5943-30-6）

di-sec-butyldisulfide（5943-30-6）
Secnidazole

Secnidazole
Sepax Unix SEC Columns

Sepax Unix SEC Columns
Fipronil 95%97% API Insecticide made in china

Fipronil 95%97% API Insecticide made in china
Omeprazole 99%min EP Pharmaceutical API Acid secretion inhibitors made in china

Omeprazole 99%min EP Pharmaceutical API Acid secretion inhibitors made in china
Herbal Factory Lignans Flaxseed Gum Secoisolariciresinol Diglucoside Powder Skin Sdg Flax Seed Extra

Herbal Factory Lignans Flaxseed Gum Secoisolariciresinol Diglucoside Powder Skin Sdg Flax Seed Extra
Arch-insect antibody test strip

Arch-insect antibody test strip
SECRETIN ACETATE

SECRETIN ACETATE
Secnidazole

Secnidazole

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service